Nasdaq Markets

In most years, April isn't a special month to buy stocks. It's not a bad time to invest, but there's nothing that makes April better than other months. But this April is different. 

Inovio Pharmaceuticals (NASDAQ: INO) has been making a lot of headlines lately. Thanks to its efforts to develop a vaccine for COVID-19, the company's stock is up by 150% year to date.

Marijuana users in Oregon bought $84.5 million worth of licensed product in March, according to data compiled by the state's Liquor Control Commission and cited in various media. That tally was 6.4% higher than in the previous month, and 30% above the March 2019 result. March 20

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

BioCryst Pharmaceuticals (NASDAQ: BCRX) has started a clinical trial to test its antiviral medication galidesivir in patients with COVID-19. The U.S. government's National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, is fundin

The following are today's upgrades for Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.

The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.

The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.

The following are today's upgrades for Validea's Book/Market Investor model based on the published strategy of Joseph Piotroski. This value-quant strategy screens for high book-to-market stocks, and then separates out financially sound firms by looking at a host of improving f

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.

In this episode of Industry Focus: Wildcard, Jason Moser and Motley Fool contributor Brian Feroldi give a breakdown of three great small caps you probably didn't know about. They range from a service provider to a surgical company and finally a research and consultancy firm. Fi

The coronavirus pandemic has millions of us holed up at home with little physical contact to the outside world. Companies like Peloton Interactive Inc. (NASDAQ: PTON), which manufactures home fitness equipment and produces video workout classes, would seem poised to take advant

Cresco Labs (OTC: CRLBF) was likely expecting 2020 to be a strong year not just for itself but for the cannabis industry as a whole. With more states -- including its home base of Illinois -- allowing cannabis use, sales growth was supposed to soar. But while there will still be

Dave & Buster's Entertainment (NASDAQ: PLAY) recently announced preliminary fiscal fourth-quarter results that continued the mixed trends that investors have seen for over a year. Comparable-store sales fell slightly, but overall revenue improved thanks to a growing store ba

Saving money is by no means an easy thing to do. This explains why an estimated 39% of Americans have less than $400 on hand for emergencies. It also explains why millions of workers are behind in building their retirement savings. 

(RTTNews) - United Airlines would offer free, round-trip flights for medical volunteers traveling to California to help in the frontline fight against the COVID-19 crisis.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

AnaptysBio (NASDAQ: ANAB) checks many boxes that make it an attractive biotech investment: It's got a sizable cash position, reputable pharma partners, and a promising drug pipeline. Throw in a depressed stock price and the company looks even more appealing. Is now the time for